Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A neoplasm of follicle center B cells which has at least a partial follicular pattern. Follicular lymphomas comprise about 35% of adult non-Hodgkin lymphomas in the U.S. and 22% worldwide. Most patients have widespread disease at diagnosis. Morphologically, follicular lymphomas are classified as Grade 1, Grade 2, and Grade 3, depending on the percentage of the large lymphocytes present. The vast majority of cases (70-95%) express the BCL-2 rearrangement [t(14;18)]. Histological grade correlates with prognosis. Grades 1 and 2 follicular lymphomas are indolent and grade 3 is more aggressive (adapted from WHO, 2001).
Biomarker and diagnostic research for neoplasm of mature B-cells has been reported in the published literature.
2 clinical trials registered, 2 recruiting. Interventions under study include drug therapy and other interventions. Pipeline includes 1 PHASE1. Research is sponsored by a mix of industry and academic institutions.
333 publications have been identified in PubMed for neoplasm of mature B-cells. Research spans Basic Science / Preclinical (35%), Review / Meta-Analysis (22%), and Gene Therapy / Novel Therapeutics (17%).
Research Type | Count | % of Total |
|---|---|---|
Laboratory research | 118 |
Data assembled from 3 of 12 sources · Last updated Sep 20, 2026, 6:09 PM UTC
Research summaries | 74 | 22% |
New treatment approaches | 55 | 17% |
Testing and diagnosis research | 23 | 7% |
Patient case studies | 23 | 7% |
Disease patterns and progression | 21 | 6% |
Clinical study results | 17 | 5% |
Other research | 2 | 1% |
Booth L (2026). [PMID: 41792971](https://pubmed.ncbi.nlm.nih.gov/41792971/). *Oncoimmunology*. [Review / Meta-Analysis]
Rade M (2026). [PMID: 41349540](https://pubmed.ncbi.nlm.nih.gov/41349540/). *Cancer cell*. [Epidemiology / Natural History]
Booth L (2026). [PMID: 41742701](https://pubmed.ncbi.nlm.nih.gov/41742701/). *Br J Dermatol*. [Diagnostic / Biomarker]
Valuskova Z (2026). [PMID: 41410506](https://pubmed.ncbi.nlm.nih.gov/41410506/). *Neoplasma*. [Gene Therapy / Novel Therapeutics]
Akbarin MM (2026). [PMID: 42246947](https://pubmed.ncbi.nlm.nih.gov/42246947/). *Anim Genet*. [Basic Science / Preclinical]
Wang H (2026). [PMID: 41391979](https://pubmed.ncbi.nlm.nih.gov/41391979/). *Pathology*. [Review / Meta-Analysis]
Alnoor F (2026). [PMID: 41897649](https://pubmed.ncbi.nlm.nih.gov/41897649/). *Diagnostics (Basel)*. [Review / Meta-Analysis]
Ingangi V (2026). [PMID: 41789071](https://pubmed.ncbi.nlm.nih.gov/41789071/). *Front Immunol*. [Review / Meta-Analysis]
Camviel N (2026). [PMID: 41655017](https://pubmed.ncbi.nlm.nih.gov/41655017/). *Mol Ther*. [Gene Therapy / Novel Therapeutics]
Dizdarević S (2026). [PMID: 41737220](https://pubmed.ncbi.nlm.nih.gov/41737220/). *Front Immunol*. [Basic Science / Preclinical]